Describing—and Doing—the Work: AVAC in print and in the streets

In a special issue of Current Opinion in HIV and AIDS, published in January 2019, AVAC staff members Emily Bass, Laura Fitch, Anabel Gomez and Maureen Luba Milambe joined collaborators who work in advocacy and human-centered design to co-author two important articles. Each highlight our core business of bold, evidence-informed advocacy and action. The articles are:

These articles are behind a paywall for now. If you are interested in obtaining a copy and cannot get access, please contact us here, as AVAC is committed to sharing information and generating discussion without barriers. Publishing work like this in peer-reviewed journals is an advocacy tactic, as it puts critical ideas and histories into the “official” record. The good news is that the content in the articles is robustly reflected in our ongoing work and in our other publications.

In Demand creation for primary biomedical prevention: identifying lessons across intervention to inform daily oral preexposure prophylaxis programs, co-authors Emily Bass, Laura Fitch, Anabel Gomez and consultant Rebecca Loar, make the case that today’s primary prevention programming isn’t yet harnessing the potential of human-centered design, and that lessons from the rollout of voluntary medical male circumcision (VMMC) must be urgently brought to bear on newer strategies like PrEP. To find out more about how and why, check out the 2018 AVAC Report, and the work of the Prevention Market Manager.

In Civil society demand for accountability to achieve 90-90-90 targets: lessons from Eastern and Southern Africa, Maureen Luba and colleagues use case studies from Kenya, Malawi and Uganda, among other countries, to show how African AIDS activism has shaped the global response, and must continue to do so. These case studies capture work that’s opened the PEPFAR process to civil society engagement. These stories demonstrate how, through innovative North-South partnership, civil society has successfully unlocked what had been a closed and relatively unaccountable process for setting goals and allocating resources. This work is ongoing in many forms and on many fronts, including via the Coalition to Mobilize Power, Activism, Strategy and Solidarity (COMPASS) Africa, a multi-country activist effort that AVAC is proud to work on with allies in the global North and South. Learn more about this work and about PEPFAR engagement here.

Key Points from the Articles

From Demand creation for primary biomedical prevention: identifying lessons across intervention to inform daily oral preexposure prophylaxis programs:

  • The literature on demand creation for other HIV biomedical primary prevention strategies have much to teach anyone interested in seeing interventions reach the people who need them. For example, one study of the demand creation for VMMC from Zambia and Zimbabwe details the benefits derived from using demand-side thinking to segment potential end-users.
  • Studies on condoms suggest the risk failure if demand creation is neglected. The authors note falling investment in demand creation coincided with an increase in new HIV diagnoses in Burkino Faso. And other condom studies described problems such as a lack of market analytics and “inadequate sustained demand creation for targeted segments of the population including young people, men who have sex with men, and sex workers.”
  • The urgency behind all of these findings becomes clear when one considers reports like one cited in the article from a Kenyan demonstration project that found high rates of discontinuation of PrEP across key populations groups. But that does not mean people don’t want PrEP. It can’t be emphasized enough, VMMC saw significant gains after efforts at demand creation underwent a process incorporating demand-side thinking.
  • Even more chilling, the authors point out, “failure to integrate and act on the lessons learned from VMMC delivery could imperil future investment in PrEP and other key interventions… Indeed, unmerited statements about who will or will not choose to use adherence-dependent methods such as daily oral PrEP or a future microbicide are already being made with some regularity.”
  • Demand creation and services for delivering primary prevention must be designed with care, both must address the varied needs of people at risk of HIV. Until then, no one will know what works.

From Civil society demand for accountability to achieve 90-90-90 targets: lessons from Eastern and Southern Africa:

  • Relentless work from national and global advocates has resulted in critical gains in access to HIV treatment and prevention but has not been well-documented. This article begins to address that absence with several case studies. Together, they tell the story of advocates turning to innovative methods to gain the attention of decision-makers, mustering evidence and persuasive arguments, and bringing meaningful change.
  • This history makes the case for scaling-up the capacity of civil society as a priority to gain control of the epidemic.
  • The stories illustrate three unique and vital functions attributed to civil society:
    a) Through innovative North-South partnerships, civil society has unlocked what had been a closed and relatively unaccountable process for setting goals and allocating resources.

    b) Civil society invigorates discussions, replacing status quo assumptions with fresh analysis. This pressure creates new possibilities, improved strategies and greater impact from interventions.
    c) Civil society’s continual demand for accountability and its ability to push an agenda led to institutionalizing a more open process for decisions on policy, programs and funding.

  • UNAIDS reports that missing the 2020 fast track targets (fewer than 500,000 new cases and fewer than 500,000 deaths from HIV annually) by only five years will mean a million more deaths and two million more cases by 2030. As the authors make clear, the unique role played by civil society is a matter of life and death. The power of advocacy must be leveraged with a greater commitment to fund and support it.

Don’t Miss These New Resources on AVAC.org

Happy New Year! We hope that you started your year refreshed for important work ahead–and to help get you started, we’ve rounded up a few select resources from AVAC.org that we hope you’ll consider as you set your agenda for 2019. We think these cross-cutting and thought-provoking tools help to frame the most pressing issues facing HIV prevention in the year ahead.

Px Wire: 10 questions for 2019
The final Px Wire of 2018 lays out 10 questions on issues confronting the HIV prevention field. We raise questions and offer brief analysis of: NIH funding and the future of research on user-initiated prevention options; anticipated results from the ECHO and DISCOVER trials; how programs and policies for rolling out oral PrEP—and possibly the dapivirine vaginal ring—need to evolve; how condom programming should be prioritized, and so much more. The centerspread features an infographic linking the timeline of prevention research with the pace that’s needed for implementation.

Next-Generation Trial Design
Has HIV prevention research seen its last placebo-controlled efficacy trial? As trials become increasingly complex, researchers are exploring how to continue to successfully study new strategies. AVAC has two new resources to help you understand the issue and the implications for advocacy and stakeholder engagement.

amfAR’s new database on PEPFAR
The PEPFAR Monitoring, Evaluation and Reporting (MER) Database, is a new web tool created as part of the COMPASS Africa collaboration. It gives HIV advocates access to a wide range of PEPFAR program data, such as district-level data with descriptions of what each indicator means, how the results are measured, and how the data can be interpreted. These data are presented in a variety of formats including data visualization, maps and downloadable PDFs.

Special Supplement on GPP
In October, the Journal of the International AIDS Society published a special supplement, Science, Theory and Practice of Engaged Research: Good Participatory Practice and beyond. It documents good participatory practices and explores their value to stakeholder engagement at clinical trials across research areas, geographies and populations. You might also like how one of the authors of the JIAS supplement laid out the issues in this piece, cross-posted on AVAC’s blog, P-Values.

Women Need Effective Choices: Do research dollars reflect this priority?
A growing number of voices are recognizing the importance of choice in HIV prevention – including a year-beginning statement from Maureen Goodenow, the Director of the Office of AIDS Research at the National Institutes of Health. The need for better choices is especially imperative for women who carry a disproportionate burden of HIV risk compared to men. The Resource Tracking for HIV Prevention R&D Working Group’s annual report looks closely at investment trends and features an infographic depicting the status of 2017 investment in research investigating PrEP for women.

Young Women Demand Inclusion
The best way to understand the diverse needs of those who face a risk of HIV is to listen to the people themselves. At the HIV Research for Prevention conference in Madrid in October, a group from the Young Women’s Leadership Initiative organized a protest to demand their inclusion in the process of planning for research. Read their statement, get inspired and heed the call in your work in 2019!

Community Engagement and HIV Prevention Research

This December, Px Pulse features a gripping, tripartite conversation between activists Morenike Giwa-Onaiwu, Stacey Hannah and Jeremiah Johnson about what their long histories fighting for community engagement in HIV prevention research have taught them, and how these lessons can be applied today, and in the future. Tune in to hear three fierce voices with fresh perspectives on how to continue designing trials, and engaging communities, in today’s landscape of expanded, but inadequate, prevention choices.

With daily oral PrEP, VMMC, partner testing and treatment that leads to virologic suppression available as potent biomedical tools, along with condoms and a range of other structural interventions, clinical trials of biomedical HIV prevention strategies to block sexual transmission are more complex, in terms of design and conduct, than ever before.

Listen to this episode of Px Pulse on iTunes or at www.avac.org/px-pulse to learn why this conversation is at a critical moment and how to manage the opportunities for an innovative and collaborative effort with the research community.

Also, in case you missed it, check out the latest issue of Px Wire, which is hot off the presses. Our year-end edition offers 10 questions for activists to galvanize their work in the year ahead. We consider the future of NIH funding for HIV prevention and its research priorities, anticipated results from the ECHO trial, what’s next for the dapivirine ring and much more! The centerspread visualizes a single time frame for trial results and critical targets for incidence reduction and scale up of primary prevention-an essential perspective for the work ahead.

Finally, please don’t forget, your support makes our work possible. Help us continue with a year-end donation at www.avac.org/donate. You can also use smile.amazon.com for your online shopping and select AVAC as your charity of choice. A portion of your purchase price is donated to AVAC—at no additional cost to you!

Happy listening and reading, and happiest of holidays!

Community Engagement and HIV Prevention

In this episode of Px Pulse, we consider how future HIV prevention trials will need to be designed as HIV prevention evolves… and how to strengthen community engagement along with it. At the heart of the matter is that clinical trials for HIV prevention are set to get bigger and more complex, in response to advances in HIV prevention, such as PrEP.

One Timeline, Two Stories, One Message: Putting trials and targets together

One problem with HIV prevention agendas is that they either live in an eternal present or in a far-off future. It’s “work with what we’ve got, which is condoms and VMMC and a little bit of PrEP”, or it’s “nothing can change without an AIDS vaccine”. The future depends on using what’s available, better and more widely, without ever losing sight of what’s in the pipeline.

As the figures below show, in the very same timeframe that the world will miss its critical target for incidence reduction and scale-up of primary prevention, several trials will release results that could change the future. 2020 will be a time of hope and reckoning. But only if the two stories start to be told as one.

The Latest Issue of Px Wire! What to Watch in 2019

As 2018 winds down, we’re struck by the many moments, and movements, in the past year that have depended on listening, without bias and also without loss of conviction. From a bold activist challenge in an elevator, to an array of young women speaking their truths about HIV prevention—the future has hinged on being willing to listen, and on demanding to be heard.

In that spirit, our year-end edition of Px Wire offers 10 questions for activists to pose, with curiosity and conviction, in 2019. What answers do you want, what do you hear, what needs to happen next? We’ll be listening!

Download the new issue here.

Our questions take on the upcoming announcement of how future NIH funding of HIV research will shape biomedical prevention, the anticipated results of the ECHO trial looking at how different contraceptive options impact women’s risk of HIV, the future of the dapivirine vaginal ring and much more.

In our centerspread, we provide a visual for uniting biomedical prevention research and implementation—a necessary fusion for our work in the coming year, and beyond.

Also necessary: your continued support. AVAC depends on your contributions of work, ideas and, yes, funds for our work! We appreciate your support in one or more of the following ways:

  • Donate: Visit www.avac.org/donate.
  • Amazon Smile: Shop at Amazon.com? Visit smile.amazon.com and select AVAC as your charity of choice and a portion of your purchase price is donated to AVAC—at no additional cost to you!
  • US Combined Federal Campaign: If you are a US government employee, support our mission through the Combined Federal Campaign, CFC #12308.

Many thanks for your continued support, partnership and inspiration.

HIV Prevention Research and Demonstration Sites in South Africa

This map demonstrates the breadth of HIV prevention research and demonstration projects in South Africa by site and type (e.g. daily oral PrEP demo projects, ARV-based rings, long-acting injectable PrEP, preventative Vaccines, antibodies, hormonal contraceptives). This map was developed by Wits RHI with support from AVAC as part of the Coalition to Accelerate and Support Prevention Research. This graphic first appeared in AVAC Report 2017: Mixed messages and how to untangle them.

Global HIV Prevention R&D Investment by Technology Category, 2000-2017

In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion. The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download. And all the graphics are available as well.

HIV Prevention R&D Trial Participants by Region in 2017

Participation of volunteers and the engagement of communities in which trials take place is essential to conducting HIV prevention research. In 2017, there were nearly 600,000 participants in HIV prevention research trials globally, mostly originating from sub-Saharan Africa, Europe, North America and Asia. A majority of participants were enrolled in research investigating TasP and PrEP, and while there are trials aimed specifically at men who have sex with men (MSM), transgender individuals and people who inject drugs, most of the studies do not specify the need to include members of key populations.

The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download.

Investment in HIV Prevention R&D by Top Philanthropic Funders in 2017

Global philanthropic funding increased by 4.1 percent from 2016 levels and amounted to US$164 million, or 14.6 percent of overall funding. The Bill and Melinda Gates Foundation (BMGF) remained the largest funder and increased its contribution by 6.6 percent, to US$150.2 million. Wellcome Trust investment fell for the fifth consecutive year to an annual US$2 million.

The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download.